Pumitamig is the class's clearest test of whether targeting PD-L1 rather than PD-1 matters. BioNTech's timelines are also the ...
Funding Will Accelerate Development of a Nanofluidic Antiretroviral Implant Designed to Deliver Continuous HIV Protection for ...
NueCell Bio, a translational development partner that helps advance cell therapies from scientific discovery to GMP readiness ...
Takeda’s First-in-Class Narcolepsy Drug ORZEYFUL Enters Japan and China Markets Following Regulatory Approvals ...
- Celltrion, Inc. (KRX:068270) has announced its participation in the United European Gastroenterology (UEG) Week 2026 to be ...
Danaher Corporation announced a collaboration with NVIDIA to advance autonomous science and help accelerate the pace of ...
First interim analysis of the G HOPE 001 study showed significant progression free survival benefit, prompting priority reviewed NDA submission in China for what could become the world's first ...
Under the terms of the agreement, Rona will receive upfront and near-term milestone payments of up to $100M and is eligible ...
360biolabs, a BioAgilytix company, announced the opening of a new Australian laboratory in Sydney, expanding its national ...
Shanghai Ark Biopharmaceutical Secures US FDA IND Clearance for Phase II Trial of Long-Acting Influenza Prevention Drug ...
South Korea’s GCCL and LabConnect Partner to Strengthen Global Clinical Trial Operations Across APAC and North America ...
In preclinical studies, ISM9546 exhibited sub-nanomolar VAV1 degradation potency across multiple cell-based assays. Oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results